+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast-2028

  • ID: 4790890
  • Drug Pipelines
  • April 2019
  • Region: Global
  • 170 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Astellas Pharma
  • Biogen
  • Catalyst Pharmaceuticals
  • Cytokinetics
  • Hoffmann-La Roche
  • Novartis
  • MORE
‘Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Spinal Muscular Atrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Spinal Muscular Atrophy from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Spinal Muscular Atrophy- Disease Understanding and Treatment Algorithm

According to the National Institute of Health (NIH), Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center (distal).

The muscle weakness usually worsens with age. SMA is one of the most common causes of infant death and mobility impairment. It mostly affects proximal muscles and respiratory muscles. There are three common forms of spinal muscular atrophy classified by age at onset and severity of functional impairment. Type 1 spinal muscular atrophy has been termed Werdnig-Hoffmann disease and is most usually fatal by 2 years of age. Children with spinal muscular atrophy type 2 can usually achieve the ability to sit, but have limited walking. Patients with type 3 or Kugelberg-Welander syndrome develop weakness in teen or young adult years

The Spinal Muscular Atrophy market report gives the thorough understanding of the Spinal Muscular Atrophy by including details such as disease introduction, classification, causes, pathophysiology, biomarkers in Spinal Muscular Atrophy, symptoms, diagnosis and differential diagnosis. It also provides treatment algorithms and treatment guidelines for Spinal Muscular Atrophy in the US, Europe, and Japan

Spinal Muscular Atrophy Epidemiology

The Spinal Muscular Atrophy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Spinal Muscular Atrophy, Total Diagnosed Prevalent Cases of Spinal Muscular Atrophy, Type specific Diagnosed Prevalence of Spinal Muscular Atrophy, Mutation specific Prevalence of Spinal Muscular Atrophy) scenario of Spinal Muscular Atrophy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028

According to a study conducted by R. Vamshi et al titled as “Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease” published in Journal of Managed Care and Specialty Pharmacy (JMCP) which stated the SMN1 gene product—SMN protein—is crucial for motor neuron development. In approximately 95% of patients, SMA results from homozygous deletion or conversion of SMN1. In about 2% of patients, de novo deletions occur in one of the SMN1 alleles; in 3%-4%, other mutations can be found, typically with an SMN1 deletion on the other allele

Spinal Muscular Atrophy Drug Chapters

This segment of the Spinal Muscular Atrophy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases

Current management of SMA is based on supportive and multidisciplinary care with a focus on reducing complications and improving quality of life. Pulmonary disease is the major cause of mortality in SMA type I and II and affects a small proportion of patients with SMA type III. Management strategies include airway clearance, cough assistance, nocturnal non-invasive ventilatory support, and continuous non-invasive ventilation. The supportive approaches involve nutrition, orthopedic care, rehabilitation, long-term feeding tubes etc

Spinraza, manufactured by Biogen is the only approved drug for the treatment of Spinal Muscular Atrophy in adults and children. The active ingredient of the drug is Nusinersen. The drug increases full-length survival motor neuron (SMN) protein by targeting the process through which it is produced by the SMN2 gene

There is no cure, but treatments can improve some symptoms and in some cases, help the patients live longer. Researchers are working robustly to find new ways to fight the disease

To meet the increasing demand for the treatment of Spinal Muscular Atrophy, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the Incident population of Spinal Muscular Atrophy& awareness of the disease. The overall dynamics of Spinal Muscular Atrophy market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Novartis, Hoffmann-La Roche, Astellas Pharma, Cytokinetics, and some others, will significantly increase the market during the forecast period (2019-2028).

Spinal Muscular Atrophy Market Outlook

The Spinal Muscular Atrophy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight

According to this research, the market of Spinal Muscular Atrophy in 7MM is expected to change from 2019-2028

Spinal Muscular Atrophy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions

Expected launch of therapies for Spinal Muscular Atrophy such as Zolgensama (Novartis), Risdiplam (Astellas Pharma/Cytokinetics), Branaplam (Novartis) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Spinal Muscular Atrophy market

Spinal Muscular Atrophy Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Spinal Muscular Atrophy Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Spinal Muscular Atrophy Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Spinal Muscular Atrophy market
  • Organize sales and marketing efforts by identifying the best opportunities for Spinal Muscular Atrophy market
  • To understand the future market competition in the Spinal Muscular Atrophy market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Astellas Pharma
  • Biogen
  • Catalyst Pharmaceuticals
  • Cytokinetics
  • Hoffmann-La Roche
  • Novartis
  • MORE
1. Key Insights

2. Spinal Muscular Atrophy Market Overview at a Glance
2.1. Market Share (%) Distribution of Spinal Muscular Atrophy in 2017
2.2. Market Share (%) Distribution of Spinal Muscular Atrophy in 2028

3. Disease Background and Overview: Spinal Muscular Atrophy (SMA)
3.1. Introduction
3.2. Classification
3.3. Causes
3.4. Pathophysiology
3.5. Biomarkers in Spinal Muscular Atrophy
3.6. Symptoms
3.7. Diagnosis
3.8. Differential Diagnosis
3.9. Diagnostic Algorithm

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Patient Population of Spinal Muscular Atrophy
4.3. 7MM Total Diagnosed Patient Population of Spinal Muscular Atrophy

5. Country Wise-Epidemiology of Spinal Muscular Atrophy
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Spinal Muscular Atrophy Prevalent Cases in the United States
5.1.3. Spinal Muscular Atrophy Diagnosed Prevalent Cases in the United States
5.1.4. Spinal Muscular Atrophy Type specific Diagnosed Prevalence in the United States
5.1.5. Spinal Muscular Atrophy Mutation specific Prevalence in the United States
5.2. EU5 Countries
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. Spinal Muscular Atrophy Prevalent Cases in Germany
5.3.2. Spinal Muscular Atrophy Diagnosed Prevalent Cases in Germany
5.3.3. Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Germany
5.3.4. Spinal Muscular Atrophy Mutation specific Prevalence in Germany
5.4. France
5.4.1. Spinal Muscular Atrophy Prevalent Cases in France
5.4.2. Spinal Muscular Atrophy Diagnosed Prevalent Cases in France
5.4.3. Spinal Muscular Atrophy Type specific Diagnosed Prevalence in France
5.4.4. Spinal Muscular Atrophy Mutation specific Prevalence in France
5.5. Italy
5.5.1. Spinal Muscular Atrophy Prevalent Cases in Italy
5.5.2. Spinal Muscular Atrophy Diagnosed Prevalent Cases in Italy
5.5.3. Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Italy
5.5.4. Spinal Muscular Atrophy Mutation specific Prevalence in Italy
5.6. Spain
5.6.1. Spinal Muscular Atrophy Prevalent Cases in Spain
5.6.2. Spinal Muscular Atrophy Diagnosed Prevalent Cases in Spain
5.6.3. Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Spain
5.6.4. Spinal Muscular Atrophy Mutation specific Prevalence in Spain
5.7. United Kingdom
5.7.1. Spinal Muscular Atrophy Prevalent Cases in the United Kingdom
5.7.2. Spinal Muscular Atrophy Diagnosed Prevalent Cases in the United Kingdom
5.7.3. Spinal Muscular Atrophy Type specific Diagnosed Prevalence in the United Kingdom
5.7.4. Spinal Muscular Atrophy Mutation specific Prevalence in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Spinal Muscular Atrophy Prevalent Cases in Japan
5.8.3. Spinal Muscular Atrophy Diagnosed Prevalent Cases in Japan
5.8.4. Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Japan
5.8.5. Spinal Muscular Atrophy Mutation specific Prevalence in Japan

6. Treatment
6.1. Approaches for Spinal Muscular Atrophy
6.1.1. Nutrition
6.1.2. Respiratory Care Assessment
6.1.3. Respiratory muscle weakness
6.1.4. Orthopedic Care
6.1.5. Swallowing muscle weakness
6.1.6. Rehabilitation
6.1.7. Medications
6.1.8. Acute care management
6.1.9. Medical care site/hospital capacity considerations
6.2. Potential Therapeutic Strategies

7. Treatment Algorithm
7.1. American Academy of Neurology Guidelines
7.1.1. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening
7.1.2. Guidelines for follow up of follow up of infants identified as having SMA with four copies of SMN2

8. United States Association Current Recommendations for Spinal Muscular Atrophy (Guidelines)

9. Europe Association Current Recommendations for Spinal Muscular Atrophy

10. Japan Association Current Recommendations for Spinal Muscular Atrophy

11. Unmet Needs

12. Marketed Drugs
12.1. Spinraza (nusinersen): Biogen
12.1.1. Drug Description
12.1.2. Mechanism of Action
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Safety and Efficacy
12.1.6. Advantages and Disadvantages
12.1.7. Product Profile

13. Emerging Drugs
13.1. Key Cross Competition
13.2. Zolgensma: Novartis
13.2.1. Product Description
13.2.2. Other Development Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Risdiplam: Hoffmann-La Roche
13.3.1. Product Description
13.3.2. Other Development Activities
13.3.3. Clinical Development
13.3.4. Safety and Efficacy
13.3.5. Product Profile
13.4. Reldesemtiv: Astellas Pharma/Cytokinetics
13.4.1. Product Description
13.4.2. Other Development Activities
13.4.3. Clinical Development
13.4.4. Safety and Efficacy
13.4.5. Product Profile
13.5. Branaplam: Novartis
13.5.1. Product Description
13.5.2. Other Development Activities
13.5.3. Clinical Development
13.5.4. Safety and Efficacy
13.5.5. Product Profile
13.6. Amifampridine Phosphate: Catalyst Pharmaceuticals
13.6.1. Product Description
13.6.2. Clinical Development
13.7. BVS 857: Novartis
13.7.1. Product Description
13.7.2. Clinical Development
13.7.3. Safety and Efficacy
13.7.4. Product Profile

14. Spinal Muscular Atrophy: 7 Major Market Analysis
14.1. Key Findings
14.2. Market Size of Spinal Muscular Atrophy in 7MM

15. The United States Market Outlook
15.1. United States Market Size
15.1.1. Total Market size of Spinal Muscular Atrophy
15.1.2. Market Size by Therapies

16. EU-5 Countries: Market Outlook
16.1. Germany
16.1.1. Total Market size of Spinal Muscular Atrophy in Germany
16.1.2. Market Size by Therapies
16.2. France
16.2.1. Total Market Size of Spinal Muscular Atrophy
16.2.2. Market Size by Therapies
16.3. Italy
16.3.1. Total Market Size of Spinal Muscular Atrophy
16.3.2. Market Size by Therapies
16.4. Spain
16.4.1. Total Market Size of Spinal Muscular Atrophy
16.4.2. Market Size by Therapies
16.5. United Kingdom
16.5.1. Total Market Size of Spinal Muscular Atrophy
16.5.2. Market Size by Therapies

17. Japan: Market Outlook
17.1. Japan market Size
17.1.1. Total Market Size of Spinal Muscular Atrophy
17.1.2. Market Size by Therapies

18. Market Drivers

19. Market Barriers

20. Appendix
20.1. Report Methodology

21. Publisher Capabilities

22. Disclaimer

23. About the Publisher

List of Tables
Table 1:Types of SMA linked to Chromosome-5
Table 2 Total Population of Spinal Muscular Atrophy in the 7MM (2017-2028)
Table 3 Total Diagnosed Population of Spinal Muscular Atrophy in the 7MM (2017-2028)
Table 4 Spinal Muscular Atrophy Prevalent Cases in the United States (2017-2028)
Table 5 Spinal Muscular Atrophy Diagnosed Prevalent Cases in the United States (2017-2028)
Table 6 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in the United States (2017-2028)
Table 7 Spinal Muscular Atrophy Mutation specific Prevalence in the United States (2017-2028)
Table 8 Spinal Muscular Atrophy Prevalent Cases in Germany (2017-2028)
Table 9 Spinal Muscular Atrophy Diagnosed Prevalent Cases in Germany (2017-2028)
Table 10 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Germany (2017-2028)
Table 11 Spinal Muscular Atrophy Mutation specific Prevalence in Germany (2017-2028)
Table 12 Spinal Muscular Atrophy Prevalent Cases in France (2017-2028)
Table 13 Spinal Muscular Atrophy Diagnosed Prevalent Cases in France (2017-2028)
Table 14 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in France (2017-2028)
Table 15 Spinal Muscular Atrophy Mutation specific Prevalence in France (2017-2028)
Table 16 Spinal Muscular Atrophy Prevalent Cases in Italy (2017-2028)
Table 17 Spinal Muscular Atrophy Diagnosed Prevalent Cases in Italy (2017-2028)
Table 18 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Italy (2017-2028)
Table 19 Spinal Muscular Atrophy Mutation specific Prevalence in Italy (2017-2028)
Table 20 Spinal Muscular Atrophy Prevalent Cases in Spain (2017-2028)
Table 21 Spinal Muscular Atrophy Diagnosed Prevalent Cases in Spain (2017-2028)
Table 22 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Spain (2017-2028)
Table 23 Spinal Muscular Atrophy Mutation specific Prevalence in Spain (2017-2028)
Table 24 Spinal Muscular Atrophy Prevalent Cases in the United Kingdom (2017-2028)
Table 25 Spinal Muscular Atrophy Diagnosed Prevalent Cases in the United Kingdom (2017-2028)
Table 26 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 27 Spinal Muscular Atrophy Mutation specific Prevalence in the United Kingdom (2017-2028)
Table 28 Spinal Muscular Atrophy Prevalent Cases in Japan (2017-2028)
Table 29 Spinal Muscular Atrophy Diagnosed Prevalent Cases in Japan (2017-2028)
Table 30 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Japan (2017-2028)
Table 31 Spinal Muscular Atrophy Mutation specific Prevalence in Japan (2017-2028)
Table 32 Standards of care for pulmonary, gastrointestinal, nutritional, and orthopedic care and rehabilitation
Table 33 United States Association Current Recommendations for SMA
Table 34 European Association Current Recommendations for SMA
Table 35 Japanese Association Current Recommendations for SMA
Table 36 Comparison of emerging drugs under development
Table 37 Clinical Trial Description
Table 38 Clinical Trial Description
Table 39 Clinical Trial Description
Table 40 Clinical Trial Description
Table 41 Clinical Trial Description
Table 42 7 Major Market Size of Spinal Muscular Atrophy in USD Million (2017-2028)
Table 43 United States Market Size of Spinal Muscular Atrophy, USD Million (2017-2028)
Table 44 Market size of Spinal Muscular Atrophy by therapies in the United States, in USD Million (2017-2028)
Table 45 Market Size of Spinal Muscular Atrophy in Germany, in USD Million (2017-2028)
Table 46 Market size of Spinal Muscular Atrophy by therapies in Germany, in USD Million (2017-2028)
Table 47 Market Size of Spinal Muscular Atrophy in France, in USD Million (2017-2028)
Table 48 Market size of Spinal Muscular Atrophy by therapies in France, in USD Million (2017-2028)
Table 49 Market Size of Spinal Muscular Atrophy in Italy, in USD Million (2017-2028)
Table 50 Market size of Spinal Muscular Atrophy by therapies in Italy, in USD Million (2017-2028)
Table 51 Market Size of Spinal Muscular Atrophy in Spain, in USD Million (2017-2028)
Table 52 Market size of Spinal Muscular Atrophy by therapies in Spain, in USD Million (2017-2028)
Table 53 Market Size of Spinal Muscular Atrophy in the UK, in USD Million (2017-2028)
Table 54 Market size of Spinal Muscular Atrophy by therapies in the United Kingdom, in USD Million (2017-2028)
Table 55 Market Size of Spinal Muscular Atrophy in Japan, in USD Million (2017-2028)
Table 56 Market size of Spinal Muscular Atrophy by therapies in Japan, in USD Million (2017-2028)

List of Figures
Figure 1:Inheritance of SMA in an autosomal recessive pattern
Figure 2 Classification of SMA
Figure 3 Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4 Targets for therapy in SMA
Figure 5 Diagnostic Evaluation of SMA
Figure 6 Spinal Muscular Atrophy Prevalent Cases in the United States (2017-2028)
Figure 7 Spinal Muscular Atrophy Diagnosed Prevalent Cases in the United States (2017-2028)
Figure 8 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in the United States (2017-2028)
Figure 9 Spinal Muscular Atrophy Mutation specific Prevalence in the United States (2017-2028)
Figure 10 Spinal Muscular Atrophy Prevalent Cases in Germany (2017-2028)
Figure 11 Spinal Muscular Atrophy Diagnosed Prevalent Cases in Germany (2017-2028)
Figure 12 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Germany (2017-2028)
Figure 13 Spinal Muscular Atrophy Mutation specific Prevalence in Germany (2017-2028)
Figure 14 Spinal Muscular Atrophy Prevalent Cases in France (2017-2028)
Figure 15 Spinal Muscular Atrophy Diagnosed Prevalent Cases in France (2017-2028)
Figure 16 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in France (2017-2028)
Figure 17 Spinal Muscular Atrophy Mutation specific Prevalence in France (2017-2028)
Figure 18 Spinal Muscular Atrophy Prevalent Cases in Italy (2017-2028)
Figure 19 Spinal Muscular Atrophy Diagnosed Prevalent Cases in Italy (2017-2028)
Figure 20 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Italy (2017-2028)
Figure 21 Spinal Muscular Atrophy Mutation specific Prevalence in Italy (2017-2028)
Figure 22 Spinal Muscular Atrophy Prevalent Cases in Spain(2017-2028)
Figure 23 Spinal Muscular Atrophy Diagnosed Prevalent Cases in Spain (2017-2028)
Figure 24 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Spain (2017-2028)
Figure 25 Spinal Muscular Atrophy Mutation specific Prevalence in Spain (2017-2028)
Figure 26 Spinal Muscular Atrophy Prevalent Cases in the United Kingdom (2017-2028)
Figure 27 Spinal Muscular Atrophy Diagnosed Prevalent Cases in the United Kingdom (2017-2028)
Figure 28 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 29 Spinal Muscular Atrophy Mutation specific Prevalence in the United Kingdom (2017-2028)
Figure 30 Spinal Muscular Atrophy Prevalent Cases in Japan (2017-2028)
Figure 31 Spinal Muscular Atrophy Diagnosed Prevalent Cases in Japan (2017-2028)
Figure 32 Spinal Muscular Atrophy Type specific Diagnosed Prevalence in Japan (2017-2028)
Figure 33 Spinal Muscular Atrophy Mutation specific Prevalence in Japan (2017-2028)
Figure 36 Sign & Symptoms of Spinal Muscular Atrophy
Figure 37 Anticipated Therapeutic Strategies
Figure 38 SMA Newborn Screening Treatment Schematic for SMN-Up-Regulating Therapy
Figure 39 Unmet Needs of Spinal Muscular Atrophy
Figure 40 7 Major Market Size of Spinal Muscular Atrophy in USD Million (2017-2028)
Figure 41 Market Size of Spinal Muscular Atrophy in the United States, USD Millions (2017-2028)
Figure 42 Market size of Spinal Muscular Atrophy by therapies in the US, in USD Million (2017-2028)
Figure 43 Market Size of Spinal Muscular Atrophy in Germany, USD Million (2017-2028)
Figure 44 Market Size of Spinal Muscular Atrophy by therapies, in Germany, in USD Million (2017-2028)
Figure 45 Market Size of Spinal Muscular Atrophy in France, USD Million (2017-2028)
Figure 46 Market Size of Spinal Muscular Atrophy by therapies, in France, in USD Million (2017-2028)
Figure 47 Market Size of Spinal Muscular Atrophy in Italy, USD Million (2017-2028)
Figure 48 Market Size of Spinal Muscular Atrophy by therapies in Italy, in USD Million (2017-2028)
Figure 49 Market Size of Spinal Muscular Atrophy in Spain, USD Million (2017-2028)
Figure 50 Market Size of Spinal Muscular Atrophy by therapies in Spain, in USD Million (2017-2028)
Figure 51 Market Size of Spinal Muscular Atrophy in the UK, USD Million (2017-2028)
Figure 52 Market Size of Spinal Muscular Atrophy by therapies in the UK, in USD Million (2017-2028)
Figure 53 Market Size of Spinal Muscular Atrophy in Japan, USD Million (2017-2028)
Figure 54 Market Size of Spinal Muscular Atrophy by therapies in Japan, in USD Million (2017-2028)
Figure 55 Market Drivers
Figure 56 Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Biogen
  • Novartis
  • Hoffmann-La Roche
  • Astellas Pharma
  • Cytokinetics
  • Catalyst Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll